Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 2, 2014, Pages 322-329

  Gerber, Naamit K ^a   Yamada, Yoshiya ^a   Rimner, Andreas ^a   Shi, Weiji ^a   Riely, Gregory J ^a   Beal, Kathryn ^a   Yu, Helena A ^a   Chan, Timothy A ^a   Zhang, Zhigang ^a   Wu, Abraham J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASE CONTROL; NEUROPHYSIOLOGY; PATIENT MONITORING; RADIOTHERAPY;

BRAIN METASTASIS; CENTRAL NERVOUS SYSTEMS; INCOMPLETE DATA; METHODS AND MATERIALS; OVERALL SURVIVAL; STEREOTACTIC RADIOSURGERY; TYROSINE KINASE INHIBITOR; WHOLE BRAINS;

BRAIN;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB;

ADENOCARCINOMA; ADULT; ARTICLE; BRAIN BIOPSY; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; SMOKING; STEREOTACTIC RADIOSURGERY;

ADENOCARCINOMA; BRAIN NEOPLASMS; CRANIAL IRRADIATION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84899951757     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.02.022     Document Type: Article

References (25)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. J.S. Barnholtz-Sloan, A.E. Sloan, and F.G. Davis et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System J Clin Oncol 22 2004 2865 2872
3. M.P. Mehta, P. Rodrigus, and C.H. Terhaard et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases J Clin Oncol 21 2003 2529 2536
4. A.F. Eichler, K.T. Kahle, and D.L. Wang et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer Neuro Oncol 12 2010 1193 1199
5. S.J. Park, H.T. Kim, and D.H. Lee et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer 77 2012 556 560
6. C.H. Gow, C.R. Chien, and Y.L. Chang et al. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response Clin Cancer Res 14 2008 162 168
7. M. Maemondo, A. Inoue, and K. Kobayashi et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
8. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
9. T. Mitsudomi, S. Morita, and Y. Yatabe et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
10. S. Heon, B.Y. Yeap, and N.I. Lindeman et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations Clin Cancer Res 18 2012 4406 4414
11. Y.L. Wu, C. Zhou, and Y. Cheng et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803) Ann Oncol 24 2013 993 999
12. J.S. Lind, F.J. Lagerwaard, and E.F. Smit et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer Int J Radiat Oncol Biol Phys 74 2009 1391 1396
13. J.W. Welsh, R. Komaki, and A. Amini et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer J Clin Oncol 31 2013 895 902
14. P.W. Sperduto, M. Wang, and H.I. Robins et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320 Int J Radiat Oncol Biol Phys 85 2013 1312 1318
15. P.W. Sperduto, N. Kased, and D. Roberge et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with bran metastases J Clin Oncol 30 2012 419 425
16. Q. Pan, W. Pao, and M. Ladanyi Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas J Mol Diagn 7 2005 396 403
17. S.P. D'Angelo, B. Park, and C.G. Azzoli et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center J Thorac Cardiovasc Surg 141 2011 476 480
18. H.A. Yu, M.E. Arcila, and N. Rekhtman et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2013 2240 2247
19. S. Matsumoto, K. Takahashi, and R. Iwakawa et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma Int J Cancer 119 2006 1491 1494
20. M. Jamal-Hanjani, and J. Spicer Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain Clin Cancer Res 18 2012 938 944
21. T. Tanaka, A. Munshi, and C. Brooks et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity Clin Cancer Res 14 2008 1266 1273
22. P. Chinnaiyan, S. Huang, and G. Vallabhaneni et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
23. S. Heon, B.Y. Yeap, and G.J. Britt et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib Clin Cancer Res 16 2010 5873 5882
24. D.W. Andrews, C.B. Scott, and P.W. Sperduto et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial Lancet 363 2004 1665 1672
25. K.H. Kim, J. Lee, and J.I. Lee et al. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 68 2010 258 263